ArticleBlood2011
Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism.
Article in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 75 citations in OpenAlex.
- Noncrystalline light-chain proximal tubulopathy: a retrospective study from a single institute of China.Renal failure · 2026Article
- Extracorporeal Free-Light-Chain Removal in Myeloma Cast Nephropathy: Plasma Exchange and Hemodialysis Strategies in the Era of Effective Antimyeloma Therapy.Journal of clinical medicine · 2026Review
- Acute kidney injury: pathogenesis and therapeutic interventions.Molecular biomedicine · 2025Review
- B Cell-Derived and Non-B Cell-Derived Free Light Chains: From Generation to Biological and Pathophysiological Roles.International journal of molecular sciences · 2025Review
- Adding insult to injury: the spectrum of tubulointerstitial responses in acute kidney injury.The Journal of clinical investigation · 2025Review
- Role of light chain clearance in the recovery of renal function in multiple myeloma: another point of view.Clinical kidney journal · 2023Article
- Multiple myeloma with acute light chain cast nephropathy.Blood cancer journal · 2023Review
- Free Light Chains, High Mobility Group Box 1, and Mortality in Hemodialysis Patients.Journal of clinical medicine · 2022Article
- High-cutoff hemodialysis in multiple myeloma patients with acute kidney injury.Frontiers in oncology · 2022Review
- Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges.International journal of nephrology and renovascular disease · 2022Review
- Cellular antioxidant mechanisms control immunoglobulin light chain-mediated proximal tubule injury.Free radical biology & medicine · 2021Article
- The Proximal Tubule Toxicity of Immunoglobulin Light Chains.Kidney international reports · 2021Review
- Monoclonal glomerulopathy with features of cryoglobulinemic glomerulopathy in murine multiple myeloma model.Ultrastructural pathology · 2020Article
- Immunoglobulin light chains generate proinflammatory and profibrotic kidney injury.The Journal of clinical investigation · 2019Article
- Myeloma light chain cast nephropathy, a review.Journal of nephrology · 2019Review
- Animal models of monoclonal immunoglobulin-related renal diseases.Nature reviews. Nephrology · 2018Review
- Bortezomib overcomes the negative prognostic impact of renal impairment in a newly diagnosed elderly patient with multiple myeloma: A case report.Oncology letters · 2017Article
- Pharmacological inhibition of Src kinase protects against acute kidney injury in a murine model of renal ischemia/reperfusion.Oncotarget · 2017Article
- Impaired Lysosomal Function Underlies Monoclonal Light Chain-Associated Renal Fanconi Syndrome.Journal of the American Society of Nephrology : JASN · 2016Article
- Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma.Blood cancer journal · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
One of the major attendant complications of multiple myeloma is renal injury, which contributes significantly to morbidity and mortality in this disease. Monoclonal immunoglobulin free light chains (FLCs) are usually directly involved, and tubulointerstitial renal injury and fibrosis are prominent histologic features observed in myeloma. The present study examined the role of monoclonal FLCs in altering the nuclear factor κ light chain enhancer of activated B cells (NF-κB) activity of renal epithelial cells. Human proximal tubule epithelial cells exposed to 3 different human monoclonal FLCs demonstrated Src kinase-dependent activation of the NF-κB pathway, which increased production of monocyte chemoattractant protein-1 (MCP-1). Tyrosine phosphorylation of inhibitor of κB kinases (IKKs) IKKα and IKKβ and a concomitant increase in inhibitor of κB (IκB) kinase activity in cell lysates were observed. Time-dependent, Src kinase-dependent increases in serine and tyrosine phosphorylation of IκBα and NF-κB activity were also demonstrated. Proteasome inhibition partially blocked FLC-induced MCP-1 production. These findings fit into a paradigm characterized by FLC-induced redox-signaling events that activated the canonical and atypical (IKK-independent) NF-κB pathways to promote a proinflammatory, profibrotic renal environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.